無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の組換えDNA(rDNA)技術市場:製品(医薬品、非医薬品)、用途、エンドユーザー、地域別(2018年〜2023年)

Global Recombinant DNA (rDNA) Technology Market - Segmented by Product (Medical and Non-medical), Application, End-User and Geography - Growth, Trends and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 707232
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.89円で換算しております。
Back to Top
世界の組換えDNA(rDNA)技術市場:製品(医薬品、非医薬品)、用途、エンドユーザー、地域別(2018年〜2023年) Global Recombinant DNA (rDNA) Technology Market - Segmented by Product (Medical and Non-medical), Application, End-User and Geography - Growth, Trends and Forecast (2018 - 2023)
出版日: 2018年08月01日 ページ情報: 英文 110 Pages
概要

世界の組換えDNA(rDNA)市場は、2018年から2023年の予測期間を通じて約7.2%のCAGRで推移すると予測されています。遺伝子組換え作物の開発、バイオ農薬およびバイオ燃料の製造、遺伝子療法の普及、バイオ医薬品のパイプライン、多様な治療用タンパク質の製造等が当市場の主な成長要因となっています。

当レポートでは、世界の組換えDNA(rDNA)市場を調査し、市場の概要、製品・用途・エンドユーザー・地域別の市場規模の推移と予測、市場の動向、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 組換えDNA(rDNA)技術市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場力学

  • 市場の成長要因
    • ゲノミクスの技術的進歩
    • バイオ医薬品産業の拡大
    • 遺伝子組換え製品の用途および需要の増加
  • 市場の阻害要因
    • 遺伝子治療に関連する科学的および規制・倫理上の問題
    • 遺伝子組換え食品の使用に関するリスク
  • 市場機会
  • 主な課題

第7章 市場分析:セグメント別

  • 製品別
    • 医薬品
    • 非医薬品
  • コンポーネント別
    • 発現システム
    • クローニングベクター
  • 用途別
    • 食品・農業
    • 健康・疾患
    • 環境
    • その他
  • エンドユーザー別
    • 製薬・バイオテクノロジー企業
    • 学術機関・政府系研究機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 企業プロファイルと競合情勢

  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • Merck KGaA
  • New England Biolabs
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi

第9章 市場の将来展望

目次
Product Code: 62776

The global recombinant DNA (rDNA) market is projected to grow at a CAGR of approximately 7.2% during the forecast period (2018-2023). The global recombinant DNA (rDNA) market is experiencing considerable growth due to the factors like widespread application of this genetically modified crop development, bio pesticides & biofuel production, and gene therapy, presence of biopharmaceuticals pipeline and production of various therapeutic proteins.

Increasing Demand as Well as Application of Recombinant/ Genetically Modified Products Boost the Growth of Recombinant DNA (rDNA) Technology Market

Recombinant DNA technology is performing a vital role in improving health conditions by developing new vaccines and pharmaceuticals. The treatment strategies are also improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Also many other industries are getting benefit from the Genetically Modified Organism (GMO) research. Such as micro-organisms are being considered as future clean fuel producers and bio degrader. Genetically modified vaccines are developed for curing various diseases in human and plants. The recombinant DNA technology created new opportunities for innovations to produce a wide range of therapeutic products with immediate effect in the medical genetics and biomedicine by modifying microorganisms, animals, and plants to yield medically useful substances.

Risks Pertaining to the Usage of Genetically Modified Food Hindering Recombinant DNA (rDNA) Technology Market

The genes are being transferred occur naturally in other species but there are unknown consequences to altering the natural state of an organism through gene expression. Such alterations can change the organism's metabolism, growth rate and also the response to the external environmental factors. These consequences influence the GMO but also the environment in which the organism is allowed to proliferate. Potential health risks to humans include the possibility of exposure of new allergens in genetically modified foods and also the transfer of antibiotic-resistant genes to gut flora. Thus it all these risks associated with the use of genetically modified food is hindering the growth of the market. Additionally, regulatory, scientific, and ethical challenges associated with gene therapy is also hindering the growth of the Recombinant DNA (rDNA) Market.

North America has the Largest Share in Global Recombinant DNA (rDNA) Technology Market

The largest share of North America is attributed due to the fact that there is a substantial number of biopharmaceutical manufacturing participants that are headquartered in the USA. Moreover, presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology has also driven the growth of the North America region. Also in August 2017, US FDA approved first gene therapy available in the United States which is developed for the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah for patients suffering from patients with a form of acute lymphoblastic leukemia (ALL).

Key Developments in the Recombinant DNA (rDNA) Technology Market

Jun 2018: Eli Lilly and Company acquired ARMO BioSciences.

Aug 2017: FDA approved Kymriah (tisagenlecleucel) for the treatment of advanced B-cell precursor acute lymphoblastic leukemia in patients for certain pediatric and young adult.

Major Players: AMGEN INC, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.), GENSCRIPT, MERCK KGAA, NEW ENGLAND BIOLABS, NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., and SANOFI among others.

Reasons to Purchase Recombinant DNA (rDNA) Technology Market Report

Current and future global recombinant DNA (rDNA) market outlook in the developed and emerging markets

Analyzing various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of Recombinant DNA (rDNA) Technology Market Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Recombinant DNA (rDNA) Technology Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porters Five Forces
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Recombinant DNA (rDNA) Technology Market Dynamics

  • 6.1 Recombinant DNA (rDNA) Technology Market Driver
    • 6.1.1 Technological Advancements in Genomics
    • 6.1.2 Expansion of Biopharmaceutical Industry
    • 6.1.3 Increasing Demand as well as Application of Recombinant/ Genetically Modified Products
  • 6.2 Recombinant DNA (rDNA) Technology Market Restraint
    • 6.2.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy
    • 6.2.2 Risks Pertaining to the Usage of Genetically Modified Food
  • 6.3 Recombinant DNA (rDNA) Technology Market Opportunities
  • 6.4 Key Challenges

7. Recombinant DNA (rDNA) Technology Market Segmentation

  • 7.1 By Product
    • 7.1.1 Medical
      • 7.1.1.1 Therapeutic Agent
      • 7.1.1.2 Human Protein
      • 7.1.1.3 Vaccine
    • 7.1.2 Non-medical
      • 7.1.2.1 Biotech Crops
      • 7.1.2.2 Specialty Chemicals
      • 7.1.2.3 Others
  • 7.2 By Component
    • 7.2.1 Expression System
    • 7.2.2 Cloning Vector
  • 7.3 By Application
    • 7.3.1 Food & Agriculture
    • 7.3.2 Health & Disease
    • 7.3.3 Environment
    • 7.3.4 Others
  • 7.4 By End-User
    • 7.4.1 Biotechnology and Pharmaceutical Companies
    • 7.4.2 Academic & Government Research Institutes
    • 7.4.3 Others
  • 7.5 By Geography
    • 7.5.1 North America Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.1.1 United States Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.1.2 Canada Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.1.3 Mexico Recombinant DNA (rDNA) Technology Market (2018-2023)
    • 7.5.2 Europe Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.2.1 France Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.2.2 Germany Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.2.3 United Kingdom Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.2.4 Italy Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.2.5 Spain Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.2.6 Rest of Europe
    • 7.5.3 Asia-Pacific Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.3.1 China Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.3.2 Japan Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.3.3 India Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.3.4 Australia & New Zealand Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.3.5 South Korea Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.3.6 Rest of Asia-Pacific
    • 7.5.4 Middle East & Africa Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.4.1 GCC Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.4.2 South Africa Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.4.3 Rest of Middle East & Africa
    • 7.5.5 South America Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.5.1 Brazil Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.5.2 Argentina Recombinant DNA (rDNA) Technology Market (2018-2023)
      • 7.5.5.3 Rest of South America

8. Company Profiles & Competitive Landscape

  • 8.1 Amgen Inc.
  • 8.2 Eli Lilly and Company
  • 8.3 F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • 8.4 GenScript
  • 8.5 Merck KGaA
  • 8.6 New England Biolabs
  • 8.7 Novartis AG
  • 8.8 Novo Nordisk A/S
  • 8.9 Pfizer Inc.
  • 8.10 Sanofi

List Not Exhaustive

9. rDNA Technology Market Future

Back to Top